GEN-MKT-18-7897-A
Dec 11, 2017 | Blogs, Software, Technology | 0 comments
The latest releases of Analyst Software 1.7 and SCIEX OS Software 1.4 introduce a new licensing model called concurrent licensing. If you want flexibility and cost savings when purchasing and using your processing software, concurrent licensing is for you.
How does it work? Concurrent licenses float through the network and are passed from user to user, machine to machine. In other words, access to the software can be granted based on the number of licenses expected to be used at the same time.
So what, you ask? Good question.
The concurrent licensing model can be significantly less costly for your organization than the single device model. This means your tier 2 and tier 3 lab analyst with lower software utilization rates can now share access easily especially when access is not needed at the same time. Get a Better Understanding of Concurrent Software Licenses >
By choosing the concurrent licensing model, your organization can be more:
Enjoy the benefits of SCIEX software solutions and take full advantage of the flexible licensing model for your processing software.
For more questions on licensing, get in touch with our software sales specialists >
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network